CRISPR Therapeutics News Releases http://ir.crisprtx.com/ CRISPR Therapeutics News Releases en Vertex Expands into New Disease Areas and Enhances Gene Editing Capabilities Through Expanded Collaboration with CRISPR Therapeutics and Acquisition of Exonics Therapeutics http://ir.crisprtx.com/news-releases/news-release-details/vertex-expands-new-disease-areas-and-enhances-gene-editing -Provides Vertex with leading gene editing capabilities to develop novel therapies for Duchenne Muscular Dystrophy and Myotonic Dystrophy Type 1- -CRISPR to receive an upfront payment of $175 million , with potential for additional milestone and royalty payments- -Exonics to be acquired for an Thu, 06 Jun 2019 17:12:00 -0400 CRISPR Therapeutics News Releases 8846 CRISPR Therapeutics to Present at Upcoming Investor Conferences http://ir.crisprtx.com/news-releases/news-release-details/crispr-therapeutics-present-upcoming-investor-conferences-0 ZUG, Switzerland and CAMBRIDGE, Mass. , May 29, 2019 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that Samarth Kulkarni, Ph.D., Chief Executive Officer of CRISPR Wed, 29 May 2019 07:00:00 -0400 CRISPR Therapeutics News Releases 8831 CRISPR Therapeutics to Participate in Upcoming Investor Conferences http://ir.crisprtx.com/news-releases/news-release-details/crispr-therapeutics-participate-upcoming-investor-conferences-3 ZUG, Switzerland and CAMBRIDGE, Mass. , May 01, 2019 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to Wed, 01 May 2019 07:00:00 -0400 CRISPR Therapeutics News Releases 8781 CRISPR Therapeutics Provides Business Update and Reports First Quarter 2019 Financial Results http://ir.crisprtx.com/news-releases/news-release-details/crispr-therapeutics-provides-business-update-and-reports-first-1 -Enrollment ongoing in Phase 1/2 clinical trials of CTX001™ for patients with severe hemoglobinopathies- -IND and CTA approved for CTX110™, wholly-owned allogeneic CAR-T cell therapy targeting CD19+ malignancies- -On track to initiate Phase 1/2 clinical trial for CTX110 in 1H 2019- -$ 437.5 million Mon, 29 Apr 2019 16:01:00 -0400 CRISPR Therapeutics News Releases 8746 CRISPR Therapeutics and Vertex Announce FDA Fast Track Designation for CTX001 for the Treatment of Beta Thalassemia http://ir.crisprtx.com/news-releases/news-release-details/crispr-therapeutics-and-vertex-announce-fda-fast-track-0 ZUG, Switzerland and CAMBRIDGE, Mass. and BOSTON , April 16, 2019 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration ( FDA ) has granted Fast Track Designation for CTX001 for the Tue, 16 Apr 2019 07:00:00 -0400 CRISPR Therapeutics News Releases 8721 CRISPR Therapeutics to Participate in Upcoming Investor Conferences http://ir.crisprtx.com/news-releases/news-release-details/crispr-therapeutics-participate-upcoming-investor-conferences-2 ZUG, Switzerland and CAMBRIDGE, Mass. , April 01, 2019 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to make Mon, 01 Apr 2019 07:00:00 -0400 CRISPR Therapeutics News Releases 8686 CRISPR Therapeutics to Participate in Upcoming Investor Conferences http://ir.crisprtx.com/news-releases/news-release-details/crispr-therapeutics-participate-upcoming-investor-conferences-1 ZUG, Switzerland and CAMBRIDGE, Mass. , March 06, 2019 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to make Wed, 06 Mar 2019 07:00:00 -0500 CRISPR Therapeutics News Releases 8656 CRISPR Therapeutics Announces Presentations at the American Association for Cancer Research 2019 Annual Meeting http://ir.crisprtx.com/news-releases/news-release-details/crispr-therapeutics-announces-presentations-american-association ZUG, Switzerland and CAMBRIDGE, Mass. , Feb. 27, 2019 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of the CRISPR team will present two posters at the Wed, 27 Feb 2019 16:53:00 -0500 CRISPR Therapeutics News Releases 8631 CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2018 Financial Results http://ir.crisprtx.com/news-releases/news-release-details/crispr-therapeutics-provides-business-update-and-reports-0 -First patient infused with CTX001 in a Phase 1/2 clinical trial for patients with beta thalassemia- -First patient enrolled in a Phase 1/2 clinical trial of CTX001 for patients with sickle cell disease- -On track to initiate clinical trial for CTX110, targeting CD19+ malignancies, in 1H 2019- - Mon, 25 Feb 2019 08:02:00 -0500 CRISPR Therapeutics News Releases 8601 CRISPR Therapeutics and Vertex Announce Progress in Clinical Development Programs for the Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001 http://ir.crisprtx.com/news-releases/news-release-details/crispr-therapeutics-and-vertex-announce-progress-clinical -First patient infused with CTX001 in a Phase 1/2 clinical trial for patients with beta thalassemia- - First patient enrolled in a Phase 1/2 clinical trial of CTX001 for patients with sickle cell disease- ZUG, Switzerland and CAMBRIDGE and BOSTON, Mass., Feb. Mon, 25 Feb 2019 08:00:00 -0500 CRISPR Therapeutics News Releases 8596